BioLife supplying cold chain technology in eight clinical trials at UC-San Francisco; shares ahead 1%

|About: BioLife Solutions, Inc. (BLFS)|By:, SA News Editor

Thinly traded nano cap BioLife Solutions (BLFS +1.3%) announces that it and precision shipping container outfit SAVSU are providing their respective cold chain technologies in eight active/pending clinical trials conducted by the Diabetes Center and Department of Surgery at the University of California, San Francisco.

Investigators are using BioLife's CryoStor for the long-term storage of the starting materials for cell therapy products.

Subscribe for full text news in your inbox